Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
NCT04987229Phase 3Enrolling by invitation
- Sponsor
- Alkermes
- Start
- Oct 2021
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of olanzapine, samidorphan in schizophrenia, bipolar I disorder, sponsored by Alkermes. Started Oct 2021; status: enrolling by invitation.
02
Drugs
olanzapinesamidorphan
03
Conditions
schizophreniabipolar I disorder
Beyond the preview
Go deeper on NCT04987229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04987229.